Effect observation of idarubicin combined with cytarabine in treatment of patients with acute myelogenous leukemia
-
摘要: 目的 探讨去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病(AML)的效果及安全性。 方法 回顾性分析本院2014年7月—2016年1月60例AML患者临床资料,将采用去甲氧柔红霉素联合阿糖胞苷治疗的31例患者设为A组,将采用柔红霉素联合阿糖胞苷治疗的29例患者设为B组,比较2组临床疗效、安全性、3年生存率。 结果 A组总有效率为93.55%, 显著高于B组的72.41%(P<0.05)。2组患者均出现了较为严重的骨髓抑制、Ⅲ~Ⅳ期血液学毒副作用,但2组血液学毒性反应比较无显著差异(P>0.05)。2组化疗后非血液学不良反应如恶心呕吐、口腔感染、肠胃炎、肝肾功能受损、上呼吸道感染、泌尿系统感染、皮肤感染、肺部感染、败血症发生率比较无显著差异(P>0.05)。A组3年总生存率为48.39%, 无进展生存率为35.48%, B组3年总生存率为38.71%, 无进展生存率为29.03%, 2组差异无统计学意义(P>0.05)。 结论 去甲氧柔红霉素联合阿糖胞苷治疗AML的疗效显著,但用药期间存在明显的骨髓抑制反应,不良反应发生率也较高,与采用柔红霉素治疗患者的3年总生存率与3年无进展生存率无显著差异。Abstract: Objective To explore the effect and safety of idarubicin combined with cytarabine in treatment of patients with acute myelogenous leukemia(AML). Methods Clinical materials of 60 AML patients from July 2014 to January 2016 in our hospital were retrospectively analyzed, and 31 patients treated with idarubicin and cytarabine were selected as group A, while 29 patients treated with daunorubicin and cytarabine were selected as group B. The clinical effect, safety and 3-year survival rate were compared between the two groups. Results The total effective rate of group A was 93.55%, which was significantly higher than 72.41% in group B(P<0.05). There were severe myelosuppression and stage III to IV hematologic side effects in both groups, but there was no significant difference in hematologic toxicity between the two groups(P>0.05). There were no significant differences in incidence rates of non-hematology adverse reactions such as nausea and vomiting, oral infection, gastroenteritis, impaired liver function, upper respiratory tract infection, urinary system infection, skin infection, lung infection or sepsis between the two groups(P>0.05). The 3-year overall survival rate and progression-free survival rate in group A were 48.39% and 35.48%, which showed no significant differences when compared to 38.71% and 29.03% in group B(P>0.05). Conclusion The combination of idarubicin and cytarabine is effective in treatment of patients with AML, but there is significant myelosuppression during the treatment, and the incidence of adverse reactions is high. There are no significant differences in the 3-year overall survival rate and 3-year progression-- free survival rate between two groups.
-
-
叶春美, 石培民, 孔兴美. 地西他滨联合CAG方案治疗老年复发难治性急性髓细胞白血病的临床观察[J]. 现代肿瘤医学, 2017, 25(9): 1463-1465. Zhu Y, Gao Q, Du J, et al. Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis[J]. Annals of Hematology, 2018, 97(9): 1-8.
李连文, 刘北忠, 陈建斌, 等. 急性早幼粒细胞白血病诱导治疗阶段不同辅助治疗方案的疗效比较[J]. 广西医学, 2018, 40(10): 7-10 , 30.
努尔比亚·阿布都热西提, 维尼拉·吐尔洪, 努尔阿米娜·依明尼亚孜, 等. 阿糖胞苷分别联合去甲氧柔红霉素、柔红霉素治疗急性髓细胞白血病对恶性分子表达影响的差异[J]. 海南医学院学报, 2018, 24(5): 30-32. Farge T, Saland E, De T F, et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism[J]. Cancer Discovery, 2017, 7(7): 716-735.
李丽君, 刘蓓, 徐茜, 等. 急性髓系白血病患者化疗后微小残留病与多药耐药基因表达相关[J]. 基础医学与临床, 2017, 37(1): 62-66. Li W, Zhong C Q, Jiao J, et al. Characterization of hsa_circ_0004277 as a new biomarker for acute myeloid leukemia via circular RNA profile and bioinformatics analysis[J]. Int J Mol Sci, 2017, 18(3): E597-E603.
杨晓阳, 万梦婕, 陈方平. 大剂量阿糖胞苷联合柔红霉素治疗初治急性髓系白血病一例[J]. 海南医学, 2017, 28(10): 1707-1708. Wei Y, Gao L, Wang L, et al. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy[J]. Drug Delivery, 2017, 24(1): 681-687.
罗自勉, 谭振清, 娄典, 等. 地西他滨联合去甲氧柔红霉素对DNMT3A突变阳性AML细胞的增殖和凋亡的影响[J]. 医学临床研究, 2017, 34(6): 1058-1060. 吴迪, 郝锦霞, 李静, 等. 地西他滨联合小剂量IA方案治疗骨髓增生异常综合征伴原始细胞增多的临床观察[J]. 中国实验血液学杂志, 2017, 14(5): 27-29. 程龙灿, 刘娜, 陈健琳, 等. 地西他滨强化预处理方案造血干细胞移植治疗难治复发急性髓性白血病的临床研究[J]. 军事医学, 2017, 24(10): 830-834. 任欣, 赵婷, 王婧, 等. 去甲氧柔红霉素联合阿糖胞苷治疗初发急性髓系白血病的预后分析[J]. 中华血液学杂志, 2018, 39(1): 15-21. Gupta S K, Garg A, Bär C, et al. Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression: [J]. Circulation Research, 2018, 122(2): 246-254.
Xu X D, Zhao Y, Zhang M, et al. Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin[J]. International Journal of Molecular Sciences, 2017, 18(2): 370-372.
王良妥, 张湘兰, 司徒健瑜, 等. 不同剂量去甲氧柔红霉素联合阿糖胞苷治疗初诊急性髓系白血病效果比较[J]. 山东医药, 2016, 56(10): 54-55. 孙爱宁, 田孝鹏, 曹祥山, 等. 含不同剂量去甲氧柔红霉素的IA方案诱导治疗成人初发急性髓系白血病的疗效和安全性研究[J]. 中华血液学杂志, 2017, 38(12): 1023. 李亮. 去甲氧柔红霉素与柔红霉素在初治急性髓系白血病诱导治疗中的疗效与安全性分析[J]. 内科急危重症杂志, 2017, 23(5): 403-404. -
期刊类型引用(1)
1. 邱换换，葛高琪，郭瑾，刘建芳，路亚婉. 基于主观整体营养评估量表评分的营养干预对结直肠癌患者化疗期营养摄入和生活质量的影响. 国际医药卫生导报. 2025(01): 136-140 . 
百度学术
其他类型引用(0)
计量
- 文章访问数: 542
- HTML全文浏览量: 108
- PDF下载量: 10
- 被引次数: 1
下载:
苏公网安备 32100302010246号